SLC5A2 and heart failure: Two ongoing SGLT2 inhibitor trials [EMPEROR‐PRESEVED (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction) (NCT03057951) and DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure) (NCT01297257)] will provide further clarity.